{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:02:18Z","timestamp":1790182938657,"version":"4.1.0"},"reference-count":22,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"unspecified","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,8,23]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To systematically evaluate the clinical efficacy, cost-effectiveness and impact on medical insurance budgets of transarterial chemoembolisation (TACE) combined with apatinib versus TACE alone for the treatment of unresectable hepatocellular carcinoma (uHCC) in China, from an integrated health technology assessment (HTA) perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>An HTA incorporating evidence from a randomised controlled trial, a Markov model with parametric extrapolation of survival data over a lifetime horizon and a static 5-year budget impact model from the Chinese healthcare payer perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Analysis was conducted from the perspective of the Chinese public healthcare payer. Clinical evidence was derived from a multicentre, randomised, open-label, prospective, phase III trial conducted at 15 hospitals in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>The published trial included 196 patients with uHCC. Participants were predominantly male (overall 85%), with a mean age of 52.7 years in the combination group and 52.9 years in the TACE-alone group. All had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and were of Chinese ethnicity. The present analysis used the de-identified, aggregated data from this published trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>The experimental regimen comprised TACE (intra-arterial injection of lipiodol and epirubicin) combined with oral apatinib (500\u2009mg\/day, initiated 4\u2009days after the first TACE). The control regimen was TACE alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Clinical outcomes included median progression-free survival (PFS) and overall survival (OS). The primary economic outcome was the incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) gained. The primary budgetary outcome was the 5-year cumulative incremental expenditure on the national basic medical insurance fund.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Clinical evidence showed that the combination therapy significantly prolonged median PFS (6.1 vs 3.4 months; HR 0.45, 95%\u2009CI 0.33 to 0.63; p&lt;0.0001) and OS (28.9 vs 24.0 months; HR 0.55, 95%\u2009CI 0.40 to 0.77; p=0.0005). The economic evaluation indicated that at the 2021 centralised procurement price, the ICER for the combination regimen was US$42\u2009864\/QALY, exceeding the willingness-to-pay threshold (US$37\u2009653\/QALY); however, when applying the 2025 national centralised procurement price, the ICER decreased to US$30\u2009650\/QALY, rendering it cost-effective. Budget impact analysis results showed that under the base-case penetration rate (reaching 50% by year 5), the cumulative incremental expenditure over 5 years would be approximately US$365\u2009million, a finding highly sensitive to both the penetration rate and drug price.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The TACE-apatinib regimen provides clear clinical benefit for uHCC in China, but its cost-effectiveness and budget feasibility are contingent on drug price. Successful national centralised procurement is the key policy lever to enable value-based access, as demonstrated by this integrated evidence framework.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ChiCTR1800018621.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-117330","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:11:04Z","timestamp":1790179864000},"page":"e117330","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["TACE combined with apatinib versus TACE alone for unresectable hepatocellular carcinoma in China: a cost-effectiveness and budget impact analysis"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8508-9945","authenticated-orcid":false,"given":"Yanxiao","family":"Zhang","sequence":"first","affiliation":[{"name":"College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0946-5755","authenticated-orcid":false,"given":"Xiaoge","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5462-5418","authenticated-orcid":false,"given":"Zimeng","family":"Huang","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1732-5797","authenticated-orcid":false,"given":"Li","family":"Huang","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2163-1124","authenticated-orcid":false,"given":"Guojun","family":"Sun","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"2026092309102077000_16.9.e117330.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2026092309102077000_16.9.e117330.2","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.15.04040","article-title":"Temporal trends of liver cancer burden, comparative analysis of risk factors and trend forecasts to 2024 in China, USA, the Republic of Korea, and Mongolia: an analysis based on multiple data sources from Global Burden of Disease 2019, the Global Cancer Observatory, and Cancer Incidence in Five Continents","volume":"15","author":"Yao","year":"2025","journal-title":"J Glob Health"},{"key":"2026092309102077000_16.9.e117330.3","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S2468-1253(21)00109-6","article-title":"Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"6","author":"Qin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026092309102077000_16.9.e117330.4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/15384047.2017.1323589","article-title":"Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial","volume":"18","author":"Lu","year":"2017","journal-title":"Cancer Biol Ther"},{"key":"2026092309102077000_16.9.e117330.5","doi-asserted-by":"crossref","first-page":"101869","DOI":"10.1016\/j.clinre.2022.101869","article-title":"Transarterial chemoembolization (TACE) plus apatinib-combined therapy versus TACE alone in the treatment of intermediate to advanced hepatocellular carcinoma patients: A real-world study","volume":"46","author":"Wang","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2026092309102077000_16.9.e117330.6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/15384047.2018.1529099","article-title":"The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study","volume":"20","author":"Yang","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"2026092309102077000_16.9.e117330.7","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.clinthera.2019.04.036","article-title":"Apatinib Combined With Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multicenter Retrospective Study","volume":"41","author":"Fan","year":"2019","journal-title":"Clin Ther"},{"key":"2026092309102077000_16.9.e117330.8","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-025-04159-y","article-title":"Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial","volume":"23","author":"Kan","year":"2025","journal-title":"BMC Med"},{"key":"2026092309102077000_16.9.e117330.9","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068910","article-title":"Health technology assessment to inform decision making in China: progress, challenges, and sustainability","volume":"381","author":"Chen","year":"2023","journal-title":"BMJ"},{"key":"2026092309102077000_16.9.e117330.10","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"2026092309102077000_16.9.e117330.11","doi-asserted-by":"crossref","unstructured":"He Y , Lin W , Cai Z , et al . Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma. Front Pharmacol 2023;14. doi:10.3389\/fphar.2023.1219694","DOI":"10.3389\/fphar.2023.1219694"},{"key":"2026092309102077000_16.9.e117330.12","doi-asserted-by":"crossref","first-page":"869960","DOI":"10.3389\/fpubh.2022.869960","article-title":"Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis","volume":"10","author":"Zhao","year":"2022","journal-title":"Front Public Health"},{"key":"2026092309102077000_16.9.e117330.13","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.794131","article-title":"The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China","volume":"10","author":"Meng","year":"2022","journal-title":"Front Public Health"},{"key":"2026092309102077000_16.9.e117330.14","doi-asserted-by":"crossref","first-page":"963058","DOI":"10.3389\/fpubh.2022.963058","article-title":"Cost-effectiveness analysis of drug-eluting beads and conventional transarterial chemoembolization in the treatment of hepatocellular carcinoma","volume":"10","author":"Shao","year":"2022","journal-title":"Front Public Health"},{"key":"2026092309102077000_16.9.e117330.15","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.849189","article-title":"Cost-Effectiveness Analysis of Hepatic Arterial Infusion Chemotherapy of Infusional Fluorouracil, Leucovorin, and Oxaliplatin Versus Transarterial Chemoembolization in Patients With Large Unresectable Hepatocellular Carcinoma","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026092309102077000_16.9.e117330.16","doi-asserted-by":"crossref","DOI":"10.1186\/s12913-022-08661-4","article-title":"Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma","volume":"22","author":"Zhou","year":"2022","journal-title":"BMC Health Serv Res"},{"key":"2026092309102077000_16.9.e117330.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-074245","article-title":"Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China","volume":"13","author":"Li","year":"2023","journal-title":"BMJ Open"},{"key":"2026092309102077000_16.9.e117330.18","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.778505","article-title":"Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis","volume":"13","author":"Peng","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026092309102077000_16.9.e117330.19","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21834"},{"key":"2026092309102077000_16.9.e117330.20","unstructured":"National Health Commission of China . Guidelines for diagnosis and treatment of primary liver cancer (2024 edition). Beijing: NHC, 2024. Available: https:\/\/www.nhc.gov.cn\/wjw\/c100378\/202404\/910cce13164044b895101236f12093e9.shtml"},{"key":"2026092309102077000_16.9.e117330.21","doi-asserted-by":"crossref","first-page":"452","DOI":"10.21037\/hbsn-20-480","article-title":"2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights","volume":"9","author":"Xie","year":"2020","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2026092309102077000_16.9.e117330.22","first-page":"1340","article-title":"Challenges and difficulties in conversion therapy for hepatocellular carcinoma [in Chinese]","volume":"34","author":"Li","year":"2025","journal-title":"Chin J Gen Surg"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-117330","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:11:09Z","timestamp":1790179869000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-117330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bmjopen-2026-117330"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-117330","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}